Vietnam Insulin Drug And Delivery Device Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Vietnam Insulin Drug and Delivery device market is segmented into type (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins), device type (insulin pens, insulin pumps, insulin syringes, and jet injectors). The report offers the value (in USD million) and volume (in Units million) for the above segments.

Vietnam Insulin Drug And Delivery Device Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Vietnam Insulin Drug And Delivery Device Market Size

Vietnam Insulin Drug And Delivery Device Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 2.00 %

Major Players

Vietnam Insulin Drug And Delivery Device Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Vietnam Insulin Drug And Delivery Device Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Vietnam Insulin Drug And Delivery Device Market Analysis

The Vietnam Insulin Drug And Delivery Device Market is expected to register a CAGR of greater than 2% during the forecast period.

Vietnam had effectively managed the spread of the COVID-19 outbreak from its inception, with no fatalities for months. However, the fourth wave of the COVID-19 pandemic ravaged Vietnam since then. According to the Ministry of Health (MOH), Vietnam has seen four waves of the COVID-19 pandemic. The source of COVID-19 (coronavirus disease), a highly infectious viral sickness, has been identified as Coronavirus-2, which causes SARS-CoV-2. Diabetes is a major risk factor for fatal COVID-19 findings. People with diabetes are more susceptible to infection due to hyperglycemia, an impaired immune system, vascular difficulties, and coexisting illnesses such as hypertension, dyslipidemia, and cardiovascular disease. In humans, angiotensin-converting enzyme 2 (ACE2) is a SARS-CoV-2 receptor.

Because high levels of physical exercise and low-fat diets in Vietnam protected against obesity, a risk factor for the disease, many Vietnamese immigrants with type 2 diabetes mellitus had little understanding of it. The majority are impoverished, elderly, non-English speakers with profound cultural roots. These are significant barriers to early diabetes diagnosis and good diabetes care. The current study highlights a number of issues that these patients frequently face, such as transportation issues, a preference for Eastern herbal remedies, a dislike for "hot" oral drugs and insulin injections, and the use of doctors with Viet Nam training who may be out of touch with recent advances in diabetes treatment. Older women may be more vulnerable because of their historically low literacy rates and lack of normal assertiveness in a culture dominated by men.

Vietnam Insulin Drug And Delivery Device Industry Overview

The market is highly consolidated, with three major manufacturers holding a global market presence and the remaining manufacturers confined to other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have the alliance to develop and commercialize Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.

Vietnam Insulin Drug And Delivery Device Market Leaders

  1. Novo Nordisk

  2. Sanofi

  3. Eli Lilly

  4. Medtronics

  5. Roche

  6. *Disclaimer: Major Players sorted in no particular order
Vietnam Insulin Drug And Delivery Device Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Vietnam Insulin Drug And Delivery Device Market News

  • March 2023: A memorandum of understanding (MoU) was signed between the Administration of Medical Service under the Ministry of Health, the Vietnam Association of Diabetes and Endocrinology, and the French pharmaceutical company Sanofi Vietnam to cooperate on the implementation of the online training program on diabetes treatment and management, iSTEP-D Plus Online.
  • June 2022: France-based Sanofi-Aventis Vietnam and local pharmacy chain FPT Long Chau signed a Memorandum of Understanding on cooperation to implement their 'Insulin Pen Sustainability Pilot Project' on plastic waste reduction.

Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Insulin Drugs
    • 5.1.1 Basal or Long Acting Insulins
    • 5.1.1.1 Lantus (Insulin Glargine)
    • 5.1.1.2 Levemir (Insulin Detemir)
    • 5.1.1.3 Toujeo (Insulin Glargine)
    • 5.1.1.4 Tresiba (Insulin Degludec)
    • 5.1.1.5 Basaglar (Insulin Glargine)
    • 5.1.2 Bolus or Fast Acting Insulins
    • 5.1.2.1 NovoRapid/Novolog (Insulin Aspart)
    • 5.1.2.2 Humalog (Insulin Lispro)
    • 5.1.2.3 Apidra (Insulin Glulisine)
    • 5.1.3 Traditional Human Insulins
    • 5.1.3.1 Novolin/Actrapid/Insulatard
    • 5.1.3.2 Humulin
    • 5.1.3.3 Insuman
    • 5.1.4 Biosimilar Insulins
    • 5.1.4.1 Insulin Glargine Biosimilars
    • 5.1.4.2 Human Insulin Biosimilars
    • 5.1.5 Insulin combinations
    • 5.1.5.1 NovoMix (Biphasic Insulin Aspart)
    • 5.1.5.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    • 5.1.5.3 Xultophy (Insulin Degludec and Liraglutide)
  • 5.2 Insulin Device
    • 5.2.1 Insulin Pumps
    • 5.2.1.1 Insulin Pump Devices
    • 5.2.1.2 Insulin Pump Reservoirs
    • 5.2.1.3 Insulin Infusion sets
    • 5.2.2 Insulin Pens
    • 5.2.2.1 Cartridges in reusable pens
    • 5.2.2.2 Disposable insulin pens
    • 5.2.3 Insulin Syringes
    • 5.2.4 Insulin Jet Injectors

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetic Population
  • 6.2 Type-2 Diabetic Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Takeda
    • 7.1.2 Novo Nordisk
    • 7.1.3 Pfizer
    • 7.1.4 Eli Lilly
    • 7.1.5 Janssen Pharmaceuticals
    • 7.1.6 Astellas
    • 7.1.7 Boehringer Ingelheim
    • 7.1.8 Merck And Co.
    • 7.1.9 AstraZeneca
    • 7.1.10 Bristol Myers Squibb
    • 7.1.11 Novartis
    • 7.1.12 Sanofi
  • *List Not Exhaustive
  • 7.2 Company Share Analysis

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Vietnam Insulin Drug And Delivery Device Industry Segmentation

Human insulin is a medication of the hormone class. Human insulin is used instead of the insulin that the body normally generates. It aids in transporting blood sugar to various physiological tissues, where it is utilized as an energy source. It also inhibits the liver from producing extra sugar. Vietnam insulin drug and delivery device market is segmented into type (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins), device type (insulin pens, insulin pumps, insulin syringes, and jet injectors). The report offers the value (in USD million) and volume (in Units million) for the above segments.

Insulin Drugs Basal or Long Acting Insulins Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins Insulin Glargine Biosimilars
Human Insulin Biosimilars
Insulin combinations NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Insulin Device Insulin Pumps Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Need A Different Region or Segment?
Customize Now

Frequently Asked Questions

What is the current Vietnam Insulin Drug And Delivery Device Market size?

The Vietnam Insulin Drug And Delivery Device Market is projected to register a CAGR of greater than 2% during the forecast period (2025-2030)

Who are the key players in Vietnam Insulin Drug And Delivery Device Market?

Novo Nordisk, Sanofi, Eli Lilly, Medtronics and Roche are the major companies operating in the Vietnam Insulin Drug And Delivery Device Market.

What years does this Vietnam Insulin Drug And Delivery Device Market cover?

The report covers the Vietnam Insulin Drug And Delivery Device Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Vietnam Insulin Drug And Delivery Device Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Vietnam Insulin Drug And Delivery Device Industry Report

Statistics for the 2025 Vietnam Insulin Drug And Delivery Device market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Vietnam Insulin Drug And Delivery Device analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Vietnam Insulin Drug And Delivery Device Market Report Snapshots